8-K filing — iSpecimen Inc. (ISPC)
Filed: 2026-09-10 AccNo: 0001213900-26-098847 Size: 197 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Stocks · News reference
iSpecimen Completes Global Cancer Research Project Of Cancer Blood Specimens; Samples Dispatched Within Three Weeks Of Getting Purchase Order
iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
iSpecimen To Acquire Foldlab AI Assets For $4.5M, Including AI Models, Software And Intellectual Property
On September 4, 2026, iSpecimen Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Agreement") with Foldlab AI Ltd., a company organized under the laws of